(Q44457013)

3 December 2017

title

Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse (English)

1 reference

3 December 2017

2

1 reference

3 December 2017

Ana Maria Comaru-Schally

7

object named as

Ana Maria Comaru-Schally

1 reference

3 December 2017

author name string

David González-Barcena

1

1 reference

3 December 2017

Manuel Vadillo-Buenfil

3

1 reference

3 December 2017

Adolfo Cortez-Morales

4

1 reference

3 December 2017

Victor Hernández L

5

1 reference

3 December 2017

Imelda Cardenas-Cornejo

6

1 reference

3 December 2017

publication date

1 August 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

56

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

183-191

1 reference

Mechanisms of antineoplastic action of somatostatin analogs

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10232

Crossref

reference URL

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

21 January 2018

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Molecular biology of somatostatin receptor subtypes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Peptide analogs in the therapy of prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Molecular biology of somatostatin receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Radiolabeled somatostatin analogs in prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Somatostatin receptor subtypes: specific expression and signaling properties

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Hormonal therapy of prostatic carcinoma. Defining the challenge.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

The somatostatin receptor family.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10232

Identifiers

DOI

10.1002/PROS.10232

1 reference

3 December 2017

1 reference